Eurekam, a company that develops solutions to control the processes of medication production, has raised €6.4 million from Impact Partners. The funds will be used to deploy Eurekam's technology globally and launch a solution dedicated to other hospital services. Eurekam was founded in 2012 by Loïc Tamarelle and Benoît Le France. The company has developed Drugcam, a technology that enables the secure composition of injectable drug preparations, particularly chemotherapy bags. Drugcam combines computer vision software and hardware to guide preparers during chemotherapy bag production, preventing toxic composition errors for patients.
Impact Partners is an investment fund that invests in innovative companies that have a positive impact on society. The fund has invested in numerous companies that are developing innovative solutions in healthcare, mobility, and the environment.
Eurekam's technology is an exciting development in the healthcare industry, as it ensures the safety of medication production for patients. The company's focus on chemotherapy bags is particularly important, as errors in the composition of chemotherapy medications can have serious consequences for patients. The company's solution, Drugcam, has the potential to significantly reduce these errors and improve patient outcomes. With the new funding, Eurekam can expand its reach and potentially save many more patient lives.
Impact Partners' investment in Eurekam is a testament to the company's potential to have a positive impact on society. The investment fund's focus on companies that are developing innovative solutions with positive societal impact is commendable and will hopefully encourage more investors to support companies that prioritize social responsibility.
